ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Communication between the immune system and the brain is critical for neuronal health, yet the molecular signals that mediate this crosstalk are not fully understood. Here, we uncover an unexpected and direct neuroprotective axis linking the thymus to the central nervous system (CNS). We show that the thymus-derived peptide Thymosin alpha-1 (Tα1) functions as a non-canonical ligand for the Hypocretin (Orexin) Receptor 1 (HCRTR1), a classical neuropeptide receptor on neurons. This engagement shields neurons from cell death by suppressing the activity of Receptor-Interacting Protein Kinase 3 (RIPK3), a central executioner of necroptosis. The physiological relevance of this pathway is highlighted in ischemic stroke, where we found that circulating Tα1 levels were significantly reduced in patients and mice, strongly correlating with disease severity. Genetic deletion of the Tα1-encoding gene Ptma exacerbated stroke injury, whereas therapeutic administration of Tα1 conferred robust neuroprotection and improved functional recovery. Our findings identify a novel thymus-brain signaling pathway, revealing a new neuroprotective function for an immune peptide and an unexpected role for a canonical neuronal receptor. This work establishes Tα1 as a promising dual-action therapeutic candidate, capable of both direct neuronal protection and systemic immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.